BrightGene Bio-Medical of Suzhou completed an $80 million pre-IPO funding led by Sequoia China. BrightGene develops and makes innovative drugs along with difficult-to-make generic drug APIs and FDFs (finished-dose forms). It its pipeline, BrightGene is developing immunoncology treatments, orally available GLP-1RA peptides for type 2 diabetes, antibody drug conjugates for solid tumors, and novel non-antibody dependent tumor targeting conjugates for brain cancer and solid tumor brain-metastases.
Source: China Biotoday
